Anti-HLA-A*02:01/p53 R175H Bispecific T-cell Engager CLSP-1025

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** An asymmetric bispecific single-chain diabody (scDb) Fc fusion protein and T-cell engager (TCE) directed against the human TP53 (p53) R175H mutant peptide (p53(R175H)168-176) bound to human leukocyte antigen (HLA)-A*02:01 (HLA-A*02:01) and the T-cell-specific antigen CD3epsilon (CD3e), with potential immunostimulating and antineoplastic activities. Upon administration, anti-HLA-A*02:01/p53 R175H bispecific TCE CLSP-1025 specifically targets and binds to CD3 on cytotoxic T-lymphocytes (CTLs) with its anti-CD3 domain and the p53(R175H)168-176 mutant peptide bound to HLA-A*02:01 expressed on tumor cells with its anti-peptide HLA (pHLA) domain. This activates and redirects CTLs to HLA-A*02:01/p53 R175H-expressing tumor cells, which results in the CTL-mediated cell death of these p53 R175H-expressing tumor cells. p53, a tumor suppressor gene, is mutated in many tumor cells, resulting in the loss of apoptosis regulation and abnormal cell proliferation.

**Synonyms:** - Anti-p53 R175H T-cell Engager CLSP-1025 - Anti-p53 R175H TCE CLSP-1025 - Anti-p53 R175H/CD3 Fusion Protein CLSP-1025 - Bispecific T-cell Engager Anti-HLA-A*02:01/p53 R175H CLSP-1025 - Bispecific TCE CLSP-1025 - CLSP 1025 - CLSP-1025 - CLSP1025 - Precise HLA Redirecting Engager CLSP-1025 - p53 R175H/HLA-A*02:01-specific T-cell Engager CLSP-1025 - pHLAre (TM) CLSP-1025